Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator) · Treatment adverse events: fever, chills, malaise after drug administration
  Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 3.12 [1.87, 5.21]
  2 studies · 132 participants
  Low
Direct match · question page
- Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator) · Failure of acute rejection reversal
  Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.84 [0.92, 3.67]
  2 studies · 132 participants
  Moderate
Direct match · question page
- Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator) · Recurrent rejection
  Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.06 [0.59, 1.88]
  2 studies · 129 participants
  Moderate
Direct match · question page
- Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator) · Treatment adverse events: neurological side effects
  Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 13.1 [1.43, 120.05]
  2 studies · 132 participants
  Low

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Failure of acute rejection reversal · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.84 [0.92, 3.67]
2 studies · 132 participants
Moderate

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Recurrent rejection · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 1.06 [0.59, 1.88]
2 studies · 129 participants
Moderate

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 3.12 [1.87, 5.21]
2 studies · 132 participants
Low

Muromonab‐CD3 (T cell) vs other antibody (stratified by comparator)

Neurological adverse effects · kidney transplant recipients: first rejection episode

Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).

1 finding from 1 review

Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
RR 13.1 [1.43, 120.05]
2 studies · 132 participants
Low